Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective (Q40899599)

24 September 2017

1 reference

title

Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective (English)

1 reference

24 September 2017

1 reference

Samara E

1

1 reference

24 September 2017

Granneman R

series ordinal

2

1 reference

24 September 2017

publication date

1 April 1997

1 reference

Clinical Pharmacokinetics

24 September 2017

published in

1 reference

24 September 2017

volume

32

1 reference

24 September 2017

issue

4

1 reference

24 September 2017

page(s)

294-312

1 reference

Steady-state population pharmacokinetics of sustained release theophylline in adult asthmatic patients

24 September 2017

cites work

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of carboplatin in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

The pharmacokinetics of propofol in children using three different data analysis approaches.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Relevance of pharmacokinetic studies in volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of amikacin in intensive care unit patients studied by NPEM algorithm.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of theophylline. II: Intravenous infusion to patients with stable chronic airway obstruction.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of lithium

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Comparison of aminoglycoside pharmacokinetics in Asian, Hispanic, and Caucasian patients by using population pharmacokinetic methods

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of intravenous indomethacin in neonates with symptomatic patent ductus arteriosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: a population analysis in kidney transplant patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of gentamicin. Use of the nonparametric expectation maximisation (NPEM) algorithm.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Application of NONMEM to routine bioavailability data

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommendations

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Determination of phenobarbitone population clearance values for South African children

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Application of NONMEM method for evaluation of relative biological availability of ofloxacin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Application of the NONMEM method to evaluation of the bioavailability of drug products

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Nonparametric estimation of population characteristics of the kinetics of lithium from observational and experimental data: individualization of chronic dosing regimen using a new Bayesian approach.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population Pharmacokinetic Analysis of Didanosine (2′,3′-Dideoxyinosine) Plasma Concentrations Obtained in Phase I Clinical Trials in Patients with AIDS or AIDS-Related Complex

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics. Theory and clinical application

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

A population pharmacokinetic study of alminoprofen penetration into synovial fluid

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Predictive performance of population pharmacokinetic parameters of tianeptine as applied to plasma concentrations from a post-marketing study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Postinduction carbamazepine clearance in an adult psychiatric population

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Exploratory analysis of population pharmacokinetic data from clinical trials with application to isradipine

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics: development of a medical intensive care unit-specific gentamicin dosing nomogram

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

A Two-Step Iterative Algorithm For Estimation In Nonlinear Mixed-Effect Models With An Evaluation In Population Pharmacokinetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Estimation of population characteristics of pharmacokinetic parameters from routine clinical data

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Experimental design and efficient parameter estimation in population pharmacokinetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Tenoxicam pharmacokinetics in rats: a population model

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

The importance of modeling interoccasion variability in population pharmacokinetic analyses

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of vancomycin in neonates.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Gentamicin population pharmacokinetic models for low birth weight infants using a new nonparametric method

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Use of nonlinear, mixed-effects modeling for population analysis of ofloxacin: effects of age on oral drug pharmacokinetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of ceftizoxime in premature newborns

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacodynamic model for ketorolac analgesia

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Premarketing observational studies of population pharmacokinetics of new drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of midazolam in neonates.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of zileution, a selective 5-lipoxygenase inhibitor, in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

A comparison of population and standard two-stage pharmacokinetic analyses of vigabatrin data

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Determination of theophylline clearance in South African children

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population kinetics of gentamicin in neonates

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of quinidine

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

The pharmacokinetics of meropenem in infants and children: a population analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of imipramine in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Pharmacokinetics of quinidine in male patients. A population analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

The use of population pharmacokinetics in drug development

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

The kinetics of flurbiprofen in synovial fluid

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetic analysis of new aminoglycosides, astromicin and isepamicin, and evaluation of Bayesian prediction method for approximation of individual clearance of drug.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Bayesian estimation of doxorubicin pharmacokinetic parameters

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Concentration- or effect-controlled clinical trials with sparse data

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacodynamics of romazarit

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Pharmacokinetic studies in elderly people. Are they necessary?

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Time and theophylline concentration help explain the recovery of peak flow following acute airways obstruction. Population analysis of a randomised concentration controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Evaluation of population pharmacokinetics in therapeutic trials. IV. Application to postmarketing surveillance

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of gentamicin in premature infants

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Modelling of individual pharmacokinetics for computer-aided drug dosage

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Pharmacokinetic and pharmacodynamic data and models in clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Characterization of the pharmacokinetics and pharmacodynamics of a new oral thromboxane A2-receptor antagonist AA-2414 in normal subjects: population analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Prediction of carboplatin clearance from standard morphological and biological patient characteristics

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of hydroxyurea in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Lack of pharmacokinetic interaction between zileuton and phenytoin in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixed-effects model

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Lithium population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetic modeling: the importance of informative graphics

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population Pharmacokinetics/Dynamics*

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

One-point Feedback Control Method for Phenytoin Dosage Adjustment

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population approaches in drug development. Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Estimation of population pharmacokinetics using the Gibbs sampler.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Variability in the pharmacokinetics of epirubicin: a population analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Characterization and validation of a pharmacokinetic model for controlled-release oxycodone

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Development of a population pharmacokinetic database for tianeptine

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Optimal sampling times for pharmacokinetic experiments

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of rectal theophylline in neonates

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population analysis of the dose-dependent pharmacokinetics of zonisamide in epileptic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of theophylline. I: Intravenous infusion to children in the acute episode of asthma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Phenobarbitone population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosing regimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

Population pharmacokinetics of phenytoin in Singapore Chinese.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9113438

12 December 2020

10.2165/00003088-199732040-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

24 September 2017

1050298974

0 references

1 reference